^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD79b-targeted antibody-drug conjugate

    Related drugs:
    2d
    Association between CD79B expression and polatuzumab vedotin efficacy, and therapy-induced changes in CD79B expression in diffuse large B-cell lymphoma. (PubMed, Virchows Arch)
    Among 24 patients with recurrent tumor biopsies, 13% showed loss of/decreased CD79B expression. In conclusion, immunohistochemical CD79B expression was not significantly associated with PV-containing therapy efficacy, which remained effective even in DLBCL with low CD79B expression.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD79B (CD79b Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive • CD20 negative
    |
    Polivy (polatuzumab vedotin-piiq)
    3d
    Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report. (PubMed, Front Immunol)
    The patient was treated with Pola-R-CHP followed by CNS-directed therapy, including high-dose methotrexate and intrathecal chemotherapy...Tumor-associated RANKL expression may be associated with the osteolytic features observed in this case. Early biopsy and systemic evaluation of cutaneous lesions are essential, as they may reflect aggressive systemic disease.
    Journal
    |
    TNFSF11 (TNF Superfamily Member 11)
    |
    Polivy (polatuzumab vedotin-piiq) • methotrexate IV
    8d
    Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P3, N=306, Completed, GWT-TUD GmbH | Active, not recruiting --> Completed
    Trial completion
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 negative
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)
    8d
    Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment (clinicaltrials.gov)
    P2, N=138, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    10d
    A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas. (PubMed, Sci Rep)
    POLA demonstrated robust single-agent antitumor activity in vivo, including in PDX models derived from patients with ibrutinib-resistant MCL. This signature likely reflects core pathways associated with POLA resistance and highlights potential novel therapeutic vulnerabilities. These findings strongly support further clinical investigation of POLA in combination with VEN as a BCL2- and MCL1-targeting therapeutic strategy in patients with R/R MCL and BCL2-positive R/R DLBCL.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD79B (CD79b Molecule)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Polivy (polatuzumab vedotin-piiq)
    23d
    Pola-ZRCHP: Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes (clinicaltrials.gov)
    P2, N=35, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq)
    1m
    Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation. (PubMed, Ann Hematol)
    Previous studies have shown that the combination of the second-generation BTKi zanubrutinib and polatuzumab vedotin, within the R-CHOP regimen, yielded higher response rates in preliminary clinical studies; however, the efficacy of this combination remains unclear. Notably, the combination showed superior synergistic efficacy in GCB-subtype cells. In conclusion, these findings provide a novel mechanistic rationale for combining zanubrutinib and polatuzumab vedotin in DLBCL treatment, regardless of cell-of-origin subtype.
    Journal
    |
    CD79B (CD79b Molecule)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq)
    1m
    ALLG NHL44: A Phase 2, Multicenter, Single-Arm Study to Evaluate Polatuzumab vedotin-Rituximab with/without Radiotherapy as a Bridging Therapy in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Prior to CD19 CAR-T Cell Therapy (ACTRN12626000586314)
    P2, N=47, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Polivy (polatuzumab vedotin-piiq)
    1m
    POLARIX: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1000, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)
    1m
    SILVERGLO: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    2ms
    A Prospective, Multicenter, Single-arm Phase II Study Evaluating the Efficacy and Safety of Polatuzumab Vedotin in Combination with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-ZRCHP) in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (ChiCTR2600119915)
    P2, N=48, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq)
    2ms
    A single-arm, prospective, phase II study of Glofitamab in combination with Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin,and Prednisone (Pola-R-CHP) to optimize primary therapy in patients with high-risk Diffuse Large B-Cell Lymphoma assessed by interim FDG PET and ctDNA (ChiCTR2600118538)
    P2, N=42, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P2 trial • Circulating tumor DNA
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)